Neal Lindeman

Vice Chair, Molecular Pathology and Laboratory Medicine

Weill Cornell Medicine
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Background: In 2017, DNA mismatch repair/microsatellite instability (MMR/MSI) testing was nationally recommended for advanced colorectal cancers based on favorable immune checkpoint inhibitor responses among patients with MMR-deficient/MSI-high tumors. Methods: Patients ages ≥20-years-old presenting with stage IV colorectal adenocarcinoma from 2010 to 2017 were identified from the National Cancer Database. 2017 was the latest year with available testing utilization data. Patient, tumor, socioeconomic, and care setting characteristics were evaluated for association with upfront MMR/MSI testing in 2017 using multivariable logistic regression and average adjusted predicted probabilities (% AAP ). Results: Among 72,830 stage IV colorectal cancers, upfront MMR/MSI testing levels increased from 16.4% in 2010 to 56.4% in 2017. For patients diagnosed in 2017 (i.e., following national recommendations, n = 10,022), testing levels were lower for older patients ( P adj AAP , 99.9% confidence interval (CI) 45.5–53.7] than patients from the 3rd (56.9% AAP , 99.9% CI, 53.3–60.6; P adj AAP , 99.9% CI, 54.3–60.9; P adj AAP , 99.9% CI, 41.0–52.1) compared with academic/NCI-designated comprehensive cancer centers (62.8% AAP , 99.9% CI, 59.7–65.8; P adj Conclusions: Upfront MMR/MSI testing utilization for patients with advanced colorectal cancer has increased but there is still substantial need for optimization. Testing utilization disproportionately lagged for patients who were older, from the poorest quartile of households, or managed at community cancer programs. Impact: Our findings indicate opportunities for improving rates of MMR/MSI testing and reporting, possibly through incorporation into quality control and accreditation metrics.

Year:

2025

PURPOSE Retrospective studies have found associations between the number of intratumoral immune cells and patient outcomes for specific cancers treated with targeted therapies. However, the clinical value of routinely quantifying intratumoral immune biomarkers using a digital pathology platform in the pan-cancer setting within an active clinical laboratory has not been established. METHODS We developed ImmunoProfile, a daily clinical workflow that integrates automated multiplex immunofluorescence tissue staining, digital slide imaging, and machine learning–assisted scoring to quantify intratumoral CD8 + , PD-1 + , CD8 + PD-1 + , and FOXP3 + immune cells and PD-L1 expression in formalin-fixed, paraffin-embedded tissue samples in a standardized and reproducible manner. We prospectively applied ImmunoProfile to biopsies collected from 2,023 unselected patients with cancer over a 3-year period in the clinical laboratory and correlated the results with patient survival. RESULTS In the pan-cancer cohort, patients with high numbers of intratumoral CD8 + or PD-1 + cells in had significantly lower risks of death compared with those with low numbers (CD8 + : high v low hazard ratio [HR], 0.62 [95% CI, 0.48 to 0.81], Wald P = .002; PD-1 + : high v low HR, 0.65 [95% CI, 0.51 to 0.83]; P = .0009) after adjusting for risk factors, including cancer type. In subset analyses, patients with high numbers of intratumoral CD8 + , PD-1 + , and/or CD8 + PD-1 + cells showed lower risks of death from non–small cell lung, colorectal, breast, esophagogastric, head and neck, pancreatic, and ovarian cancers after considering clinical risk factors, including American Joint Committee on Cancer stage, and despite varying therapies (all P < .05). CONCLUSION Routinely quantifying intratumoral CD8 + and PD-1 + cells with a clinically validated digital pathology platform predicts patient survival across major cancer types, independent of clinical stage and despite diverse treatment regimens.

Year:

2025

Summary and list of detected and reported alterations by alteration type (CNV, SNV/Indel) and assay (both assays, Central Lab (CL) or Assay H only, Pilot Lab only). For both detected and reported variants, positive percent agreement (PPA) with Pilot Lab and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.

Year:

2025

Scatter plots of continuous copy number results obtained from Central Lab (CL) or assay H and Designated Lab (DL) assay. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is for variants detected by both assays but not reported by at least one assay, and orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.

Year:

2025

Purpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. Experimental Design: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for single-nucleotide variant, insertion and deletion, and copy-number variant classes. Results: We observed high concordance in variant detection between CL and DL for single-nucleotide variants and insertions and deletions [average positive agreement (APA) > 95.4% for all pairwise comparisons] but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2% 82%) except between CL and two assays (APA = 76.9% and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. Conclusions: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatic analysis.

Year:

2025

Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.

Year:

2025

Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated. Cytogenetics results for all concordance study samples and gene amplification measurements using different techniques: NGS, ddPCR, microarray and FISH

Year:

2025

A, Scatter plot of continuous VAF results between Central Lab (CL) or assay H and Pilot Lab. B, Scatter plot of continuous CN results. The large plot focuses on copy numbers up to 50, while the small inset shows the full range of CNV. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is detected but not reported by Pilot Lab, while orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.

Year:

2025

Each worksheet shows all variants reported by a given Designated Laboratory, including those that are outside of the overlap region between the Central Assay and the Designated Laboratory Assay

Year:

2025

Scatter plots of continuous CN results obtained by NGS Central Lab (CL) or assay H, or NGS assay U and non-NGS techniques: A) ddPCR, B) microarray, C) FISH (Raw values) and D) FISH (Ratio). The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (34)

Alessandro Di Federico

University of Bologna

ITALY
View details

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Wenjuan Zhang

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Noah Brown

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Bose Kochupurakkal

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Biren Saraiya

Assistant Professor of Medicine

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Rahul Parikh

Associate Professor of Medicine

University of Kansas Medical Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Szabolcs Szelinger

Research Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details

Peining Li

Professor

Yale University School of Medicine

UNITED STATES
View details

Toni Choueiri

Director, Lank Center for Genitourinary Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Nancy Lin

Associate Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Deborah Schrag

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

J. Bryan Iorgulescu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew D Cherniack

Group Leader

Dana-Farber Cancer Institute

UNITED STATES
View details

Michelle Afkhami, MD

Chief and Professor, Division of Molecular Pathology and Therapy Biomarkers

City of Hope

UNITED STATES
View details

Mahesh Mansukhani

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Eddy Saad

Dana-Farber Cancer Institute

UNITED STATES
View details

Scott Rodig

Professor of Pathology

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Peter Sorger

Otto Krayer Professor of Systems Pharmacology

Harvard Medical School

UNITED STATES
View details

Liqiang Xi

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Glenn Hanna

Dana-Farber Cancer Institute

UNITED STATES
View details

RAVINDRA KOLHE

Augusta University

UNITED STATES
View details

Brittany Bychkovsky

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Eric Konnick

Associate Professor

University of Washington

UNITED STATES
View details

Adam Olson

Assistant Professor

UPMC Hillman Cancer Center

UNITED STATES
View details

S. Percy Ivy

Associate Chief

National Cancer Institute

UNITED STATES
View details

Zenta Walther

Associate Professor

Yale University School of Medicine

UNITED STATES
View details

Filipa Lynce

Dana-Farber Cancer Institute

UNITED STATES
View details

Eric Winer

Director

Yale University

UNITED STATES
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details

Mamta Parikh

Associate Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details